The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.
A study of more than 5,000 breast cancer patients found that multi-gene sequencing has rapidly replaced BRCA1/2-only tests, resulting in better pathogenic variant detection but also higher VUS rates.
A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
As a clinical study seeks to decide whether low levels of PCT can guide antibiotic therapy, researchers are exploring alternate, gene expression biomarkers.
A test being developed by researchers at Stanford University and Enable Biosciences could be used for HIV screening sooner than traditional immunoassays.
The team has developed a method to test for inherited disorders prenatally and plan to conduct a larger trial and eventually offer it as a clinical test.
